Stout served as the exclusive financial advisor to the founders and shareholders of Nimbus Health GmbH on its sale to Dr. Reddy’s Laboratories.
The demand for medical cannabis has been on the rise for years since the legalization of medical cannabis by the German Parliament (Bundestag) in 2017. The German market is already valued at ~€122 million, with a compound annual growth rate (CAGR) of ~55% since 2017, making Germany one of the largest markets in Europe. Around 150,000 German patients already benefit from medical cannabis for their unmet health needs1.
Founded in 2018 by Linus Maximilian Weber and Dr. Alessandro Rossoni and backed by Mavericks Founders, an Angel syndicate from Berlin, Nimbus Health is one of the pioneers for medical cannabis in Germany and beyond. The Company is a fully licensed pharmaceutical wholesaler and manufacturer with its own warehouse facilities and an independent sales force promoting the highest-grade medical cannabinoid-based products to pharmacists in order to supply and help seriously ill patients. Nimbus has established a fast-growing, tech-driven, and highly compliant setup that is ideally positioned for further joint growth.